A letter to the editor in today’s The Boston Globe by Janet Wozniak suggests that since the U.S. Food and Drug Administration (FDA) approved the use of two atypical antipsychotic medications last year for pediatric bipolar disorder, it is proof the disorder exists: The FDA approvals of Risperdal and Abilify for this purpose not only suggest [...] ...
Anytime
